A Phase II/III Pivotal, Open-label, Randomized, 3 Arm Study to Assess the Efficacy of LNP3794 Monotherapy or in Combination with Docetaxel, Compared with Docetaxel Alone, in Patients with RAS Mutation Positive Locally Advanced and Metastatic Non-Small Cell Lung Cancer - NA
Phase of Trial: Phase II/III
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs LNP 3794 (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Lupin
- 05 Nov 2019 Planned number of patients changed from 114 to 141.
- 05 Nov 2019 Status changed from active, no longer recruiting to discontinued.
- 26 Mar 2019 Status changed from recruiting to active, no longer recruiting.